Filing Flows › Recursion Pharmaceuticals (RXRX) › Q3 2026
Recursion Pharmaceuticals (RXRX) Q3 2026 earnings results (third quarter 2026)
10-Q filed Nov 2, 2026
Recursion Pharmaceuticals (RXRX) reported revenue of $18.6M for the third quarter 2026 (Q3 2026), +258% from a year earlier and +142% from the quarter before. Operating margin was -663.9%, net loss $119M (641.6% of revenue).
Recursion Pharmaceuticals, Q3 2026: revenue $18.6M (+258% year over year), operating margin -663.9%, net loss $119M, operating cash flow −$77.4M. The chart follows the revenue to costs, profit and cash.
| Q3 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $18.6M | +142% | +258% |
| Operating profit | −$123M | — | — |
| Net earnings | −$119M | — | — |
| Operating cash flow | −$77.4M | — | — |
What changed
Revenue was $18.6M in Q3 2026, up 258% year over year and up 142% from the previous quarter. Operating revenue was the largest line at 97% of revenue. Operating revenue added $13.1M year over year (up 262%), 98% of the total change.
Operating costs exceeded revenue by $123.2M, an operating margin of -663.9%. Total costs fell 20% while revenue rose 258%. The quarter ended with a net loss of $119.0M, narrower than the previous quarter's $131.0M loss.
Operating cash flow was −$77.4M. Non-cash charges added back $16.5M of depreciation and amortization and $23.0M of share-based compensation. Capital expenditures of $407K exceeded it, leaving free cash flow of −$77.8M.
Questions
What was Recursion Pharmaceuticals' revenue in the third quarter 2026?
Recursion Pharmaceuticals (RXRX) reported revenue of $18.6M for the third quarter 2026 (Q3 2026), +258% from a year earlier and +142% from the quarter before.
Was Recursion Pharmaceuticals profitable in the third quarter 2026?
Operating loss was $123M (-663.9% of revenue) and net loss $119M.